RdRP-IN-4

RdRP-IN-4

• UNSPSC Description: RdRP-IN-4 (compound 11q), an aryl benzoyl hydrazide analog, is an orally active influenza A virus RNA-dependent RNA polymerase (RdRp) inhibitor by interacting with the PB1 subunit. RdRP-IN-4 exhibits potent inhibitory activity against the avian H5N1 flu strain with an EC50 of 18 nM in MDCK cells. RdRP-IN-4 displays excellent potency against the the H1N1 (A/PR/8/34) Flu A strain and Flu B strain (B/Lee/1940) with EC50 values of 53 nM and 20 nM, respectively. RdRP-IN-4 significantly inhibits the expression level of viral nucleoprotein (NP) in a dose-dependent manner. RdRP-IN-4 exhibits significant antiviral activity in infected mice[1].
• Target Antigen: Influenza Virus
• Type: Reference compound
• Related Pathways: Anti-infection
• Applications: COVID-19-anti-virus
• Field of Research: Infection
• Assay Protocol: https://www.medchemexpress.com/rdrp-in-4.html
• Solubility: 10 mM in DMSO
• Smiles: O=C(C1=CC=C(C=C1)N2CCOCC2)NNC3=C(C=CC=C3Br)Br
• Molecular Weight: 455.14
• References & Citations: [1]Xinjin Liu, et al. Discovery of Aryl Benzoyl Hydrazide Derivatives as Novel Potent Broad-Spectrum Inhibitors of Influenza A Virus RNA-Dependent RNA Polymerase (RdRp). J Med Chem. 2022 Mar 10;65(5):3814-3832.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported